New imaging probe for detecting triple-negative breast cancer
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
This study is testing a new imaging tool to see if it can help find triple-negative breast cancer more accurately and improve treatment options for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Peking University Cancer Hospital & Institute Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06203119 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the clinical predictive value of a novel imaging probe, 68Ga-DOTA-BPP, in patients with triple-negative breast cancer (TNBC). The study utilizes positron emission tomography/computed tomography (PET/CT) to assess the effectiveness of this probe in identifying ACE expression in TNBC cells. Participants will undergo PET/CT imaging to provide insights into patient screening and treatment efficacy before targeted therapies. The goal is to establish a reliable imaging platform for ACE-targeted therapies in TNBC.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18-75 with confirmed triple-negative breast cancer who require PET/CT imaging for diagnosis or staging.
Not a fit: Patients who are pregnant, nursing, or have severe hepatic or renal dysfunction may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of diagnosing and staging triple-negative breast cancer, leading to better-targeted treatments.
How similar studies have performed: Similar studies using targeted imaging probes have shown promise in improving cancer diagnosis and treatment outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. 18-75 years old; 2. ECOG score 0 or 1 point; 3. Participants with confirmed TNBC cancer who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging. Exclusion Criteria: 1. Pregnant or nursing; 2. Severe hepatic or renal dysfunction; 3. Low WBC (less than 3 x 10\^9/L); 4. Unable to comply with the PET/CT imaging procedures
Where this trial is running
Beijing, Beijing Municipality
- Ethics Committee of Peking University Cancer Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Qian Zhang
- Email: 1806708691@qq.com
- Phone: 13765839835
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.